The Venture Codex

Led · Series A · Feb 2025

MAVOCO provides a Connectivity Management Platform (CMP) built on open standards to enable cooperation between network operators and enterprise customers across countries and networks. The CMP, launched in 2021, is compatible with any core network and cloud infrastructure and is designed to avoid vendor lock-in and costly monolithic solutions. The platform has been deployed for tier-1 network operators across Southeast Asia and the Middle East, with major European network operators scheduled to go live in 2025. Founded in 2014, MAVOCO maintains offices in Vienna, Eisenstadt, Klagenfurt, and Warsaw and is Eisenstadt-based. The company is using new funding to further enhance its capabilities and deliver a next-generation CMP. MAVOCO reports it is currently bidding in tenders with a total pipeline value of over €350 million.

Led · Seed · May 2021

HeartBeat.bio is a Vienna-based biotech developing a human organoid cultivation, screening and AI-supported data analysis solution for cardiac drug development. Its cardioid drug discovery platform relies on self-assembling, highly reproducible cardiac organoids that recapitulate human physiology and enable modeling of heart diseases not achieved with other in-vitro systems. The company is currently focused on drug-induced and various subtypes of genetic cardiomyopathies, with additional programs planned in diabetic cardiomyopathy, myocardial infarction and cardiac remodeling/fibrosis. Led by CEO Michael Krebs, HeartBeat.bio intends to use the funds to complete its cardioid platform for proprietary and collaborative drug discovery programs. Financially, the company closed a €4.5M Pre-Series A round. The platform combines organoid biology and AI-enabled data analysis to accelerate development of therapeutics for heart failure and related indications. HeartBeat.bio is a Vienna, Austria-based spin-off of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) developing a high-throughput 3D screening platform for heart diseases using self-organizing human cardiac organoids called Cardioids. The Cardioid technology, invented by the Mendjan lab at IMBA, enables automated, reproducible, and cost-effective large-scale generation and analysis of cardiac organoids suitable for high-throughput compound screening. The company intends to use the €1.5m seed financing to establish operations, build an experienced team over the next 12 months, and develop Cardioid into a platform solution for compound screening. Its drug discovery program will focus on heart failure, cardiomyopathies, and cardiotoxicity studies for new drug candidates. HeartBeat.bio has signed an exclusive license and collaboration agreement with IMBA and will closely cooperate with Sasha Mendjan's research group to further develop the technology. The company has also received financial support from AWS via the AWS Pre-Seed Program and from Vienna's INiTS AplusB Scaleup Program.